KYNB Share Price Performance
US$7.08
-5.16 (-42.15%)
83.5% undervalued intrinsic discount
US$43.00
Fair Value
Price US$7.08
AnalystConsensusTarget US$43.00
Fair ValueUS$43.00
Share Pricen/a
Kyntra Bio, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
KYNB Community Narratives
AN
Fair Value
·Fair Value US$43 83.5% undervalued intrinsic discount
Clinical Trials And Regulatory Advances Will Open US Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Kyntra Bio
83.5% undervalued intrinsic discount
Clinical Trials And Regulatory Advances Will Open US Markets
View narrativeAN
Updated 10 Aug 2025
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Clinical Trials And Regulatory Advances Will Open US Markets
Fair Value: US$43 83.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Kyntra Bio, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -7.63
- -489.06%
- -669.69%
- 0%
About KYNB
- Founded
- 1993
- Employees
- 34
- CEO
- WebsiteView website
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
